R&D News | pharmaphorum

News

UK must not overlook manufacturing in life sciences drive

To meet its aspiration of becoming a life sciences superpower, the UK must not only discover and develop new medicines – it must also be able to manufacture them at scale,

News

Beacon debut sheds light on Syncona’s gene therapy plans

UK life sciences investor Syncona is bankrolling a new gene therapy company, Beacon Therapeutics, that emerged this morning with a pipeline headed by a therapy acquired fr

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

R&D

Headlines and hot topics from ASCO and BIO, with Jonah Comst...

This week, pharmaphorum editor-in-chief Jonah Comstock headed to not one, but two back-to-back events in the US.

News

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approva

News

AstraZeneca inks $2bn Treg cell therapy deal with Quell

UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which

UK must not overlook manufacturing in life sciences drive

Beacon debut sheds light on Syncona’s gene therapy plans

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Headlines and hot topics from ASCO and BIO, with Jonah Comst...

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

AstraZeneca inks $2bn Treg cell therapy deal with Quell

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks